Jason M. Broderick

Articles

TAR-200 Monotherapy Is Effective and Well Tolerated in BCG-unresponsive NMIBC

October 24th 2023

The intravesical chemotherapy delivery system TAR-200 provided sustained and durable responses in patients with Bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer.

Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High-risk NMIBC

May 1st 2023

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

TAR-200 Produces High CR Rates, Tolerability in BCG-unresponsive NMIBC

May 1st 2023

Treatment with TAR-200 produced complete responses and was well tolerated in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, according to preliminary data from the phase 2b SunRISe-1 trial.

High BMI Associated With Longer OS in Patients With RCC Undergoing Nephrectomy

April 30th 2023

A high body mass index was linked with improved overall survival in patients with renal cell carcinoma undergoing radical nephrectomy.

68Ga-FAP-2286 PET Imaging Influences Bladder Cancer Treatment Decisions

April 28th 2023

The use of 68Ga-FAP-2286 PET imaging may improve treatment selection and response assessment in patients with bladder cancer, according to findings from a pilot study evaluating the diagnostic performance of this imaging technology.

First-line Lenvatinib Plus Pembrolizumab Elicits Antitumor Activity in Non–Clear Cell RCC

September 12th 2022

Frontline lenvatinib plus pembrolizumab displayed a promising overall response rate and disease control rate in patients with non–clear cell renal cell carcinoma.

PSA Response Following Darolutamide Triplet Linked to OS Benefit in mHSPC

June 8th 2022

Treatment with darolutamide, androgen deprivation therapy, and docetaxel that elicited a PSA response was linked to improved overall survival in patients with metastatic hormone-sensitive prostate cancer.

Neoadjuvant Avelumab/Axitinib Combination Elicits Promising Response Rates in High-Risk RCC

February 20th 2022

The addition of the PD-L1 inhibitor avelumab to the TKI axitinib generated promising efficacy as a neoadjuvant therapy in patients with high-risk, non-metastatic clear-cell renal cell carcinoma.

Atezolizumab Plus Cabozantinib Shows Meaningful Clinical Activity in mCRPC, Including High-Risk Subsets

September 19th 2021

The phase 1b COSMIC-021 trial showed clinically meaningful activity with cabozantinib plus atezolizumab in patients with locally advanced or metastatic castration-resistant prostate cancer who have been previously treated, including patients with high-risk features.

CDK Inhibition May Overcome Mechanisms of Olaparib Resistance in Prostate Cancer

September 15th 2021

By studying olaparib-sensitive and -resistant cell lines, researchers were able to gather insights regarding PARP inhibitor treatment and resistance mechanisms, including the use of CDK inhibition as a potential means of overcoming PARP inhibitor resistance in prostate cancer.

177Lu-PSMA-617 Plus Standard of Care Improves OS in mCRPC

June 3rd 2021

177Lu-PSMA-617, a targeted radioligand therapy, plus standard of care induced approximately a 40% reduction in the risk of death vs SOC alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer.

FDA Grants DKN-01 Orphan Drug Status for Gastric/GEJ Cancer

June 12th 2020

The FDA has granted an Orphan Drug designation to DKN-01 for the treatment of patients with gastric cancer or gastroesophageal junction cancer.

FDA Grants Berubicin Orphan Drug Status for Brain Cancer

June 11th 2020

The FDA has granted an orphan drug designation to berubicin for the treatment of patients with malignant gliomas.

FDA Approves Nivolumab for Esophageal Cancer

June 11th 2020

The FDA has approved nivolumab for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Pembrolizumab Combo Falls Short in Phase 3 Frontline Urothelial Carcinoma Trial

June 10th 2020

Adding pembrolizumab to chemotherapy did not lead to a statistically significant improvement in overall survival or progression-free survival in patients with advanced or metastatic urothelial carcinoma, according to findings from the phase 3 KEYNOTE-361 trial.

Pembrolizumab Combo Falls Short in Phase 3 Frontline Urothelial Carcinoma Trial

June 10th 2020

Adding pembrolizumab to chemotherapy did not lead to a statistically significant improvement in overall survival or progression-free survival in patients with advanced or metastatic urothelial carcinoma, according to findings from the phase 3 KEYNOTE-361 trial.

FDA Grants Margetuximab Orphan Drug Status for Gastric Cancer

June 5th 2020

The FDA has granted margetuximab an Orphan Drug designation for the treatment of patients with gastric and gastroesophageal junction cancer.

FDA Accepts Application for Ropeginterferon Alfa-2b for Polycythemia Vera

June 5th 2020

The FDA has accepted an application for ropeginterferon alfa-2b for use as a treatment for patients with polycythemia vera.

Subcutaneous Daratumumab Approved in Europe for Myeloma

June 4th 2020

The European Commission has approved subcutaneous formulation of daratumumab for the treatment of patients with multiple myeloma.

Isatuximab Approved in Europe for Relapsed/Refractory Myeloma

June 2nd 2020

The European Commission has approved isatuximab in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥2 prior therapies.

NEXT PAGE
PREVIOUS PAGE